{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:16:14Z","timestamp":1775499374884,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,23]]},"DOI":"10.7759\/cureus.81050","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:22:21Z","timestamp":1742782941000},"source":"Crossref","is-referenced-by-count":1,"title":["Risk of Proton Pump Inhibitor (PPI)-Induced Galactorrhea: An Uncommon Adverse Effect of a Common Drug"],"prefix":"10.7759","author":[{"given":"Fezaan A","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zamanali","family":"Khakhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayed K","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Physiology, prolactin","author":"Al-Chalabi M","year":"2025","unstructured":"Al-Chalabi M, Bass AN, ALsalman I. Physiology, prolactin. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand DS","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017, 11:27-37. 10.5009\/gnl15502","journal-title":"Gut Liver"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/56.suppl_4.S11","article-title":"Safety profile of the proton-pump inhibitors","volume":"56","author":"Reilly JP","year":"1999","unstructured":"Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999, 56:S11-7. 10.1093\/ajhp\/56.suppl_4.S11","journal-title":"Am J Health Syst Pharm"},{"key":"ref4","article-title":"Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders","author":"Wolfe MM","year":"2025","unstructured":"Wolfe MM. Proton pump inhibitors: overview of use and adverse effects in the treatment of acid related disorders. UpToDate. Connor RF (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref5","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. Accessed. February 5, 2025: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2235","article-title":"Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study","volume":"39","author":"Hart E","year":"2019","unstructured":"Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019, 39:443-53. 10.1002\/phar.2235","journal-title":"Pharmacotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.37358\/RC.20.10.8362","article-title":"Potential role of proton pump inhibitors against human DRD2 receptor in drug induced hyperprolactinemia","volume":"71","author":"Ashfaq M","year":"2020","unstructured":"Ashfaq M, Abid SMA, Rauf K, et al.. Potential role of proton pump inhibitors against human DRD2 receptor in drug induced hyperprolactinemia. Rev Chim. 2020, 71:182-92. 10.37358\/RC.20.10.8362","journal-title":"Rev Chim"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-015-0622-7","article-title":"Esomeprazole induced galactorrhea: a novel side effect","volume":"9","author":"Pipaliya N","year":"2016","unstructured":"Pipaliya N, Solanke D, Rathi C, Patel R, Ingle M, Sawant P. Esomeprazole induced galactorrhea: a novel side effect. Clin J Gastroenterol. 2016, 9:13-6. 10.1007\/s12328-015-0622-7","journal-title":"Clin J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03337-3","article-title":"Omeprazole-induced galactorrhea in kidney transplant patients-a case report","volume":"16","author":"Dorji C","year":"2022","unstructured":"Dorji C, Robin FA, Na-Bangchang K. Omeprazole-induced galactorrhea in kidney transplant patients-a case report. J Med Case Rep. 2022, 16:121. 10.1186\/s13256-022-03337-3","journal-title":"J Med Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19818","article-title":"Navigating drug interactions with proton pump inhibitors","volume":"7","author":"Tan CM","year":"2024","unstructured":"Tan CM, Juurlink DN. Navigating drug interactions with proton pump inhibitors. JAMA Netw Open. 2024, 7:e2419818. 10.1001\/jamanetworkopen.2024.19818","journal-title":"JAMA Netw Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.051722","article-title":"Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions","volume":"41","author":"Shirasaka Y","year":"2013","unstructured":"Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013, 41:1414-24. 10.1124\/dmd.113.051722","journal-title":"Drug Metab Dispos"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"Majumdar A","year":"2013","unstructured":"Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013, 6:168-75. 10.4103\/0974-1208.121400","journal-title":"J Hum Reprod Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00022.x","article-title":"Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole","volume":"13 Suppl 3","author":"Ishizaki T","year":"1999","unstructured":"Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 1999, 13 Suppl 3:27-36. 10.1046\/j.1365-2036.1999.00022.x","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350506-risk-of-proton-pump-inhibitor-ppi-induced-galactorrhea-an-uncommon-adverse-effect-of-a-common-drug","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:22:24Z","timestamp":1742782944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350506-risk-of-proton-pump-inhibitor-ppi-induced-galactorrhea-an-uncommon-adverse-effect-of-a-common-drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.81050","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}